Education
About Us
Working with TipRanks
Follow Us
Arcus Biosciences Inc (RCUS)
NYSE:RCUS
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-1.09Last Year’s EPS
-1.02Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: 0.00%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
Arcus Biosciences demonstrated strong financial management and strategic advancements in their casdatifan program, with promising data and collaborations. However, there are concerns about pipeline reprioritization, particularly in the TIGIT program, and a decline in quarterly revenue.Company Guidance
During the Arcus Biosciences First Quarter 2025 Earnings and Financial Results Call, the company provided several key metrics and guidance on its financial and clinical trajectory. Arcus reported $1 billion in cash and investments, with expectations to maintain this strong financial position through its initial pivotal readouts for three major programs, including the PEAK-1 trial for casdatifan. The company anticipates recognizing GAAP revenue between $75 million to $90 million for the full year 2025, primarily driven by its collaboration with Gilead. In terms of clinical development, Arcus highlighted the rapid enrollment of the PRISM-1 trial, expected to be fully enrolled by the end of 2025, and the STAR-221 trial's timeline to read out in 2026. The company emphasized its focus on casdatifan, targeting a $5 billion market opportunity in RCC, with the completion of its Phase 3 PEAK-1 study and ongoing collaborations with AstraZeneca to advance TKI-free regimens.Cash Position and Capital Allocation
Arcus Biosciences has a strong balance sheet with $1 billion in cash and investments, bolstered by a $150 million equity financing. This financial position is expected to fund operations through initial pivotal readouts for key programs, including PEAK-1.
Casdatifan Development Progress
Significant progress in the casdatifan program, with promising initial data from the cas plus cabo cohort of ARC-20 accepted for an oral presentation at ASCO. The program includes eight cohorts evaluating different dosing regimens, combinations, and settings for clear cell RCC.
Strategic Collaborations
Arcus is collaborating with AstraZeneca to develop casdatifan in combination with their anti-PD-1 anti-CTLA-4 bispecific antibody, volrustomig, offering the first TKI-free HIF-2 alpha combination option for first-line RCC.
Enrollment and Study Progress
The PRISM-1 trial in pancreatic cancer is enrolling rapidly and expected to be fully enrolled by the end of 2025, ahead of initial expectations. There is also strong enrollment interest in the PEAK-1 trial.
---
RCUS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RCUS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 06, 2025 | $8.12 | ― | ― |
| Feb 25, 2025 | $10.24 | $10.14 | -0.98% |
| Nov 06, 2024 | $15.73 | $16.46 | +4.64% |
| Aug 08, 2024 | $13.69 | $15.61 | +14.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Arcus Biosciences Inc (RCUS) report earnings?
Arcus Biosciences Inc (RCUS) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Arcus Biosciences Inc (RCUS) earnings time?
Arcus Biosciences Inc (RCUS) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RCUS EPS forecast?
RCUS EPS forecast for the fiscal quarter 2025 (Q2) is -1.09.
---